David Soergel, MD is the Global Head of Cardiometabolic Development for Novartis, joining in 2017. In this role, he is responsible for progression of portfolio assets in the cardiovascular, renal and metabolism arenas from proof of concept through health authority registration. This activity relies on strong interconnections with colleagues at NIBR and in the commercial organization within Novartis, and regular evaluation of external opportunities in academic centers and in biotechnology companies. The approach of the development unit includes continued focus on operational efficiency, on development of associates and on understanding the needs of patients. The current projects in the development unit include indication extension of Entresto (e.g., heart failure with preserved ejection fraction, heart failure prevention post-MI); development of TQJ230 targeting lipoprotein(a) and cardiovascular risk reduction; development of LNP023 targeting complement factor B for complement-driven diseases.
Prior to this role, Dr. Soergel spent 9 years at biotechnology companies in increasing levels of responsibility working in a variety of therapy areas, building high-performing, agile development teams and conducting clinical trials in all phases of development, including complex multi-stage adaptive trials. His most recent position was senior vice president and chief medical officer of Trevena. Prior to joining biotech, Dr. Soergel worked in early stage clinical development and translational medicine at GlaxoSmithKline, leading programs from the discovery organization into the clinic and through proof of concept.
Dr. Soergel originally trained in pediatrics, pediatric cardiology and heart failure and transplant at Johns Hopkins Hospital and Children’s Hospital of Philadelphia. During his cardiology fellowship, Dr. Soergel completed an NIH sponsored NRSA post-doctoral fellowship at Johns Hopkins studying myofilament function in the laboratory of Anne Murphy, MD.